LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion for First-Line Maintenance Treatment in BRCA-Mutated Advanced Ovarian Cancer - BioSpace

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion for First-Line Maintenance Treatment in BRCA-Mutated Advanced Ovarian Cancer  BioSpace

AstraZeneca and Merck's LYNPARZA Is the Only PARP Inhibitor in This Setting to Demonstrate an Improvement in Progression-Free Survival for Patients Who ...



Comments

Popular posts from this blog

“A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times” plus 1 more

How to perform chest auscultation and interpret the findings - Nursing Times

“National Day Awards 2019, Singapore News & Top Stories - The Straits Times” plus 1 more